OncohematologyOncohematologyОнкогематология1818-83462413-4023Publishing House ABV Press72110.17650/1818-8346-2009-0-2-4-16HEMATOLOGIC MALIGNANCIES: TREATMENT, SUPPORTIVE CAREГЕМОБЛАСТОЗЫ: ЛЕЧЕНИЕ, СОПРОВОДИТЕЛЬНАЯ ТЕРАПИЯChronic myeloid leukemia — before and after imatinib (First part)Хронический миелолейкоз — до и после применения иматиниба (Часть I)LomaiaE. G.ЛомаиаЕ. Г.
Russian Federation

St-Petersburg

Санкт-Петербург

MotorinD. V.МоторинД. В.
Russian Federation

St-Petersburg

Санкт-Петербург

RomanovaE. G.РомановаЕ. Г.
Russian Federation

St-Petersburg

Санкт-Петербург

ZaritzkiyA. Yu.ЗарицкийА. Ю.
Russian Federation

St-Petersburg

Санкт-Петербург

Federal Almazov hearth, blood and endocrinology CentreФГУ Федеральный центр сердца, крови и эндокринологии им. В. А. АлмазоваSt-Petersburg Pavlov State Medical UniversityПетербургский государственный медицинский университет им. И. П. Павлова27052009241624112022241120222009https://oncohematology.abvpress.ru/ongm/article/view/721

The first successful experience effective target therapy has been achieved at imatinib administration in chronic myeloid leukemia (CML) treatment. Disease early considered practically incurable, now successful controlled using little toxic conservative therapy. During tyrosine kinase inhibitors therapy it is possible to achieve stable hematological and cytogenetic remission at the majority of CML patients, and at same patients leukemic cells do not detected by most sensitive molecular methods. In the first part of article literature data concerning CML pathogenesis, modern phases and risk group criteria, and role of interferon alpha and hematopoietic stem cells transplantation in imatinib and other tyrosine kinase inhibitors era are discussed.

Первый успешный опыт проведения эффективной таргетной терапии был достигнут при применении иматиниба в лечении хронического миелолейкоза (ХМЛ). Заболевание, ранее считавшееся практически некурабельным, в настоящее время поддается вполне успешному контролю с помощью малотоксичной консервативной терапии. На фоне лечения ингибиторами тирозинкиназ у большинства пациентов с ХМЛ возможно достижение стабильной клинико-гематологической и цитогенетической ремиссии, а у части из них лейкемические клетки не удается обнаружить и с помощью самых чувствительных молекулярных методов исследования. В I части статьи отражены данные литературы по патогенезу ХМЛ, современным критериям фаз и групп риска развития болезни, а также роли препаратов интерферона-альфа и аллотрансплантации гемопоэтических стволовых клеток в эру иматиниба и новых ингибиторов тирозинкиназ.

chronic myeloid leukemiaCML diagnosticsinterferon alphahematopoietic stem cells transplantationхронический миелолейкоздиагностика хронического миелолейкозаинтерферон-альфааллотрансплантация гемопоэти- ческих стволовых клеток1. Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845; 64: 413.Bennett J.H. Case of hypertrophy of the spleen and liver in which death took place from suppuration of the blood. Edinburgh Med Surg J 1845; 64: 413.2. Cragie D. Case of disease of the spleen in which deth took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1845; 64: 400.Cragie D. Case of disease of the spleen in which deth took place in consequence of the presence of purulent matter in the blood. Edinburgh Med Surg J 1845; 64: 400.3. Deininger M.W., Goldman J.M., Lydon N. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691–8.Deininger M.W., Goldman J.M., Lydon N. et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997;90:3691–8.4. Cortes J., Kantarjian H.M., O’Brien S. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996;100:452–5.Cortes J., Kantarjian H.M., O’Brien S. Result of interferon-alpha therapy in patients with chronic myelogenous leukemia 60 years of age and older. Am J Med 1996;100:452–5.5. Bogdanov K.V., Chukhlovin A.B., Zaritskey A.Y. et al. Ultraviolet irradiation induces multiple DNA double-strand breaks and apoptosis in normal granulocytes and chronic myeloid leukaemia blasts. Br J Haematol 1997;98(4):869–72.Bogdanov K.V., Chukhlovin A.B., Zaritskey A.Y. et al. Ultraviolet irradiation induces multiple DNA double-strand breaks and apoptosis in normal granulocytes and chronic myeloid leukaemia blasts. Br J Haematol 1997;98(4):869–72.6. Boice J.D. Jr., Day N.E., Andersen A. et al. Second cancers following radiation treatment for cervical cancer. J Natl Cancer Inst 1985;74:955–75.Boice J.D. Jr., Day N.E., Andersen A. et al. Second cancers following radiation treatment for cervical cancer. J Natl Cancer Inst 1985;74:955–75.7. Ichimaru M., Ishimaru T., Mikami M. et al. Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res 1978;19:262–82.Ichimaru M., Ishimaru T., Mikami M. et al. Incidence of leukemia in atomic bomb survivors belonging to a fixed cohort in Hiroshima and Nagasaki, 1950–71. Radiation dose, years after exposure, age at exposure, and type of leukemia. J Radiat Res 1978;19:262–82.8. Daley G.Q., Van Etten R.A., Baltimore D. et al. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–30.Daley G.Q., Van Etten R.A., Baltimore D. et al. Induction of chronic myelogenous leukemia in mice by the P210 bcr/abl gene of the Philadelphia chromosome. Science 1990;247:824–30.9. Kloetzer W.S., Kurzrock R., Smith L. et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K-562 has associated tyrosine protein kinase activity. Virology 1985;140:230–8.Kloetzer W.S., Kurzrock R., Smith L. et al. The human cellular abl gene product in the chronic myelogenous leukemia cell line K-562 has associated tyrosine protein kinase activity. Virology 1985;140:230–8.10. McWhirter J.R., Wang J.Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 1992;11:1553–65.McWhirter J.R., Wang J.Y. Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr/abl fusion proteins. Mol Cell Biol 1992;11:1553–65.11. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079–82.Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079–82.12. Smith K.M., Yacobi R., Va Etten R.A. Autoinhibition of Bcr-Abl through its SH3 domain. Mol cell 2003;12:27–37.Smith K.M., Yacobi R., Va Etten R.A. Autoinhibition of Bcr-Abl through its SH3 domain. Mol cell 2003;12:27–37.13. Steelman L.S., Pohnert S.C., Shelton J.G. et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and eukemogenesis. Leukemia 2004;18(2):189–218.Steelman L.S., Pohnert S.C., Shelton J.G. et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and eukemogenesis. Leukemia 2004;18(2):189–218.14. Kurzrock R., Kantarjian H.M., Druker B.J., Talpaz M. Philadelphia chromosomepositive leukemias: from basic mechanisms to molecular theurapeutics. Ann Intern Med 2003;138(10):819–30.Kurzrock R., Kantarjian H.M., Druker B.J., Talpaz M. Philadelphia chromosomepositive leukemias: from basic mechanisms to molecular theurapeutics. Ann Intern Med 2003;138(10):819–30.15. Durig J., Rosenthal C., Elmaagacli A. et al. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+haemopoietic cells. Leukemia 2000;14(9):1652–60.Durig J., Rosenthal C., Elmaagacli A. et al. Biological effects of stroma-derived factor-1 alpha on normal and CML CD34+haemopoietic cells. Leukemia 2000;14(9):1652–60.16. Peled A., Hardan I., Trakhtenbrot L. et al. Immature leukemic CD34+CXCR4+cells from CML patients have lower integrindependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002;20(3):259–66.Peled A., Hardan I., Trakhtenbrot L. et al. Immature leukemic CD34+CXCR4+cells from CML patients have lower integrindependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 2002;20(3):259–66.17. Lugo T.G., Pendergast A.M., Muller A.J. et al. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079–82.Lugo T.G., Pendergast A.M., Muller A.J. et al. Tyrosin kinase activity and transformation potency of bcr-abl oncogene products. Science 1990;247:1079–82.18. Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-abl. Trend Cell Biol 1999;9:179–86.Van Etten R.A. Cycling, stressed-out and nervous: cellular functions of c-abl. Trend Cell Biol 1999;9:179–86.19. Nakamura T., Lee M.P., Johnson L.A. et al. Fusion of the nucleoporin gene NUP98 to HOXA9 may the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia. Nat Genet 1996;12:154–8.Nakamura T., Lee M.P., Johnson L.A. et al. Fusion of the nucleoporin gene NUP98 to HOXA9 may the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia. Nat Genet 1996;12:154–8.20. Mitani K., Kominami R., Muramatsu M. et al. Generation of the AML1/EVI-1 fusion gene in t(3;21(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994;13:504–10.Mitani K., Kominami R., Muramatsu M. et al. Generation of the AML1/EVI-1 fusion gene in t(3;21(q26;q22) causes blastic crisis in chronic myelocytic leukemia. EMBO J 1994;13:504–10.21. Ahuja H., Advani S.H., Cline M.J. et al. Alterations in the p53 gene and the local evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989;86:6783–7.Ahuja H., Advani S.H., Cline M.J. et al. Alterations in the p53 gene and the local evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 1989;86:6783–7.22. Sill H., Goldman J.M., Cross N.C.P. Homozygous deletions of the p16 tumorsupressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995;85:2013–6.Sill H., Goldman J.M., Cross N.C.P. Homozygous deletions of the p16 tumorsupressor gene are associated with lymphoid transformation of chronic myeloid leukemia. Blood 1995;85:2013–6.23. Zhang S., Dong X., Li X. et al. A gainof-function mutations of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Blood 2007;110:abstr 1022.Zhang S., Dong X., Li X. et al. A gainof-function mutations of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Blood 2007;110:abstr 1022.24. Jamieson C.H., Ailles L.E., Dylla S.J. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351(7):657–67.Jamieson C.H., Ailles L.E., Dylla S.J. et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med 2004;351(7):657–67.25. Coluccia A.M., Vacca A., Dunach M. et.al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007;26(5):1456–66.Coluccia A.M., Vacca A., Dunach M. et.al. Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation. EMBO J 2007;26(5):1456–66.26. Babicka L., Zemanova Z., Pavlistova L. et al. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2006;168(1):22–9.Babicka L., Zemanova Z., Pavlistova L. et al. Complex chromosomal rearrangements in patients with chronic myeloid leukemia. Cancer Genet Cytogenet 2006;168(1):22–9.27. Majlis A., Smith T.L., Talpaz M. et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996;14:196–203.Majlis A., Smith T.L., Talpaz M. et al. Significance of cytogenetic clonal evolution in chronic myelogenous leukemia. J Clin Oncol 1996;14:196–203.28. Hehlmann R., Berger U., Pfirrmann M. et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003;17:1529–37.Hehlmann R., Berger U., Pfirrmann M. et al. Randomized comparison of interferon alpha and hydroxyurea with hydroxyurea monotherapy in chronic myeloid leukemia (CML-study II): prolongation of survival by the combination of interferon alpha and hydroxyurea. Leukemia 2003;17:1529–37.29. Kantarjian H.M., Shan J., Cortes J. et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia. Cancer 2001;92(10):2501–7.Kantarjian H.M., Shan J., Cortes J. et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia. Cancer 2001;92(10):2501–7.30. Wadhwa J., Szydlo R.M., Chase A. et al. Factors affecting duration of survival after onset of blastic transformation of chronic myelogenous leukemia. Blood 2002;99(7):2304–9.Wadhwa J., Szydlo R.M., Chase A. et al. Factors affecting duration of survival after onset of blastic transformation of chronic myelogenous leukemia. Blood 2002;99(7):2304–9.31. Cortes J., O`Dwyer M.E. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;8(3):671–84.Cortes J., O`Dwyer M.E. Clonal evolution in chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;8(3):671–84.32. Kantarjian H.M., Dixon D., Keating M.J. et al. Characteristic of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441–6.Kantarjian H.M., Dixon D., Keating M.J. et al. Characteristic of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441–6.33. Savage D.G., Szydlo R.M., Goldman J.M. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96:111–6.Savage D.G., Szydlo R.M., Goldman J.M. Clinical features at diagnosis in 430 patients with chronic myeloid leukemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96:111–6.34. Jones D., Luthra R., Cortes J. et al. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changed in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 2008;15(112):5190–2.Jones D., Luthra R., Cortes J. et al. BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changed in determining the phenotype of Philadelphia chromosome-positive leukemias. Blood 2008;15(112):5190–2.35. Kantarjian H.M., Keating M.J., Walters R.S. et al. Characteristic of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441–6.Kantarjian H.M., Keating M.J., Walters R.S. et al. Characteristic of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441–6.36. Baccarani M., Saglio G., Goldman J. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Lukemia Net. Blood 2006;108:1809–20.Baccarani M., Saglio G., Goldman J. et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of European Lukemia Net. Blood 2006;108:1809–20.37. Schoch C., Haferlach T., Kern W. et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003;17:461–3.Schoch C., Haferlach T., Kern W. et al. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003;17:461–3.38. Cortes J.E., Talpaz M., O`Brien S. et al. Staging of chronic myeloid leukemia in the imatinib era. Cancer 2006;106(6):1306–15.Cortes J.E., Talpaz M., O`Brien S. et al. Staging of chronic myeloid leukemia in the imatinib era. Cancer 2006;106(6):1306–15.39. Cervantes F., Hernandez-Boluda J.C., Steegmann J.L. et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003;88(10):1117–22.Cervantes F., Hernandez-Boluda J.C., Steegmann J.L. et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003;88(10):1117–22.40. Rosti G., Trabacchi E., Bassi S. et al.; Italian Cooperative Study Group on Chronic Myeloid Leukemia. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88(3):256–9.Rosti G., Trabacchi E., Bassi S. et al.; Italian Cooperative Study Group on Chronic Myeloid Leukemia. Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia. Haematologica 2003;88(3):256–9.41. Sokal J.E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49–61.Sokal J.E., Baccarani M., Russo D., Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol 1988;25:49–61.42. Hasford J., Pfirmann M., Hehlmann R. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Nat Cancer Institut 1998;90:850–8.Hasford J., Pfirmann M., Hehlmann R. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing Committee for the Collaborative CML Prognostic Factors Project Group. J Nat Cancer Institut 1998;90:850–8.43. Gratwohl A., Hermans J., Goldman J.M. et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352(9134):1087–92.Gratwohl A., Hermans J., Goldman J.M. et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998;352(9134):1087–92.44. Hehlmann R., Heimpel H., Kolb H.J. et al. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 1993;11(Suppl 1):159–68.Hehlmann R., Heimpel H., Kolb H.J. et al. The German CML study, comparison of busulfan vs. hydroxyurea vs. interferon alpha and establishment of prognostic score 1. Leuk Lymphoma 1993;11(Suppl 1):159–68.45. Bonifazi F., de Vivo A., Rosti G. et al.; European Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074–81.Bonifazi F., de Vivo A., Rosti G. et al.; European Study Group on Interferon in Chronic Myeloid Leukemia; Italian Cooperative Study Group on CML; France intergroup of CML; German CML Study Group; UK Medical Research Council Working Party on CML; Spanish CML Study Group; Australian CML Study Group; Swedish CML Study Group. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders. Blood 2001;98:3074–81.46. Абдулкадыров К.М., Удальева В.Ю., Рукавицын О.А., Бессмельцев С.С. Альфа-интерфероны в лечении больных хроническим миелолейкозом. Вопр онкол 1999;45(4):387–92.Абдулкадыров К.М., Удальева В.Ю., Рукавицын О.А., Бессмельцев С.С. Альфа-интерфероны в лечении больных хроническим миелолейкозом. Вопр онкол 1999;45(4):387–92.47. Kantarjian H.M., O’Brien S., Smith T.L. Treatment of Philadelphia- positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alpha and low doses cytarabine. J Clin Oncol 1999;17:284–92.Kantarjian H.M., O’Brien S., Smith T.L. Treatment of Philadelphia- positive early chronic phase chronic myelogenous leukemia with daily doses of interferon-alpha and low doses cytarabine. J Clin Oncol 1999;17:284–92.48. Faderl S., Talpaz M., Estrov Z. Chronic myelogenous leukemia: biology and therapy. Ann Int Med 1999;131:207–19.Faderl S., Talpaz M., Estrov Z. Chronic myelogenous leukemia: biology and therapy. Ann Int Med 1999;131:207–19.49. Kujawski L.A., Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia.Cytokine Growth Factor Rev 2007;18(5–6):459–71.Kujawski L.A., Talpaz M. The role of interferon-alpha in the treatment of chronic myeloid leukemia.Cytokine Growth Factor Rev 2007;18(5–6):459–71.50. Palandri F., Iacobucci I., Castagnetti F. et al.; GIMEMA Working Party on CML. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008;93(5):770–4.Palandri F., Iacobucci I., Castagnetti F. et al.; GIMEMA Working Party on CML. Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome. Haematologica 2008;93(5):770–4.51. Fefer A., Cheever M.A., Thomas E.D. et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979;300:333–7.Fefer A., Cheever M.A., Thomas E.D. et al. Disappearance of Ph1-positive cells in four patients with chronic granulocytic leukemia after chemotherapy, irradiation and marrow transplantation from an identical twin. N Engl J Med 1979;300:333–7.52. Maziarz R.T. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr Opin Hematol 2008;15:127–33.Maziarz R.T. Who with chronic myelogenous leukemia to transplant in the era of tyrosine kinase inhibitors? Curr Opin Hematol 2008;15:127–33.53. Goldman J. Management of chronic myeloid leukemia. Semin Hematol 2003;40:1–103.Goldman J. Management of chronic myeloid leukemia. Semin Hematol 2003;40:1–103.54. Silver R.T., Woolf S.H., Hehlmann R. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517–36.Silver R.T., Woolf S.H., Hehlmann R. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 1999;94:1517–36.55. Druker B.J., Ford J.M., Goldman J.M. et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001;87–112.Druker B.J., Ford J.M., Goldman J.M. et al. Chronic myelogenous leukemia. Hematology (Am Soc Hematol Educ Program) 2001;87–112.56. Goldman J. Management of chronic myeloid leukemia. Semin Hematol 2003;40:1–103.Goldman J. Management of chronic myeloid leukemia. Semin Hematol 2003;40:1–103.57. Gratwohl A., Brand R., Apperley J. et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513–21.Gratwohl A., Brand R., Apperley J. et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513–21.58.Weisser M., Ledderose G., Kolb H.J. Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade Ann Hematol 2007;86:127–32.Weisser M., Ledderose G., Kolb H.J. Long-term follow-up of allogeneic HSCT for CML reveals significant improvement in the outcome over the last decade Ann Hematol 2007;86:127–32.59. Weisser M., Schleuning M., Haferlach C. et al. Allogeneic stem cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leukemia and Lymphoma 2007;48(2):295–301.Weisser M., Schleuning M., Haferlach C. et al. Allogeneic stem cell transplantation provides excellent results in advanced stage chronic myeloid leukemia with major cytogenetic response to pre-transplant imatinib therapy. Leukemia and Lymphoma 2007;48(2):295–301.60. Gratwohl A. Prognostic factors in chronic myeloid leukemia: allografting. Semin Hematol 2003;40(1):13–21.Gratwohl A. Prognostic factors in chronic myeloid leukemia: allografting. Semin Hematol 2003;40(1):13–21.61. Oehler V.G., Gooley T., Synder D.S. et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782–9.Oehler V.G., Gooley T., Synder D.S. et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007;109:1782–9.62. Hehlmann R., Hochhaus A., Baccarani M. on behalf of the European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007;370:342–50.Hehlmann R., Hochhaus A., Baccarani M. on behalf of the European Leukemia Net. Chronic myeloid leukaemia. Lancet 2007;370:342–50.63. Mauro M.J., Maziarz R.T. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used? Mayo Clin Proc 2006;81(3):404–16.Mauro M.J., Maziarz R.T. Stem cell transplantation in patients with chronic myelogenous leukemia: when should it be used? Mayo Clin Proc 2006;81(3):404–16.64. Kцrbling М., Anderlini Р. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001;98:2900–8.Kцrbling М., Anderlini Р. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 2001;98:2900–8.65. Elmaagacli A.H., Beelen D.W., Opalka B. et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia chromosome-positive first chronic phase myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with marrow. Blood 1999;94:3884–9.Elmaagacli A.H., Beelen D.W., Opalka B. et al. The risk of residual molecular and cytogenetic disease in patients with Philadelphia chromosome-positive first chronic phase myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with marrow. Blood 1999;94:3884–9.66. Oehler V.G., Radich J.P., Storer B. et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005;11:85–92.Oehler V.G., Radich J.P., Storer B. et al. Randomized trial of allogeneic related bone marrow transplantation versus peripheral blood stem cell transplantation for chronic myeloid leukemia. Biol Blood Marrow Transplant 2005;11:85–92.67. Champlin R.E., Schmitz N., Horowitz M.M. et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000;95:3702–9.Champlin R.E., Schmitz N., Horowitz M.M. et al. Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood 2000;95:3702–9.68. Slattery J.T., Clift R.A., Buckner C.D. et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055–60.Slattery J.T., Clift R.A., Buckner C.D. et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055–60.69. Crawley C., Szydlo R., Lalancette M. et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969–76.Crawley C., Szydlo R., Lalancette M. et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005;106:2969–76.70. Kebriaei P., Detry M.A., Giralt S. et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007;110(9):3456–62.Kebriaei P., Detry M.A., Giralt S. et al. Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia. Blood 2007;110(9):3456–62.71. Horowitz M.M., Gale R.P., Sondel P.M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555–62.Horowitz M.M., Gale R.P., Sondel P.M. et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 1990;75(3):555–62.72. Kolb H.J. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998;74(Suppl 2):321–9.Kolb H.J. Donor leukocyte transfusions for treatment of leukemic relapse after bone marrow transplantation. EBMT Immunology and Chronic Leukemia Working Parties. Vox Sang 1998;74(Suppl 2):321–9.73. Weisser M., Tischer J., Schnittger S. et al. Acomparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006;91:663–6.Weisser M., Tischer J., Schnittger S. et al. Acomparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation. Haematologica 2006;91:663–6.74. Apperley J.F. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology (Am Soc Hematol Educ Program) 2006:226–32.Apperley J.F. Managing the patient with chronic myeloid leukemia through and after allogeneic stem cell transplantation. Hematology (Am Soc Hematol Educ Program) 2006:226–32.75. Hehlmann R., Berger U., Pfirrmann M. et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686–92.Hehlmann R., Berger U., Pfirrmann M. et al. Drug treatment is superior to allografting as first-line therapy in chronic myeloid leukemia. Blood 2007;109:4686–92.76. Giralt S.A., Arora M., Goldman J.M. et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007;137:461–7.Giralt S.A., Arora M., Goldman J.M. et al. Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007;137:461–7.